HealthWarehouse.com Reports First Quarter 2026 Financial Results Amid Strategic Shift Toward Technology and AI Partnerships
HealthWarehouse.com,a U.S.-based healthcare e-commerce and digital pharmacy company, has reported its financial results for the first quarter ended March 31, 2026. The company also outlined its ongoing strategic transformation, highlighting new technology investments and partnerships aimed at supporting long-term growth despite a significant short-term decline in revenue.
Significant Revenue Decline Following Regulatory Market Changes
For the first quarter of 2026, HealthWarehouse.com recorded net sales of $6.3 million, representing a sharp decline of approximately 58% compared to $15.0 million in the same period of 2025. The company attributed this decrease primarily to changes in the regulatory environment surrounding compounded GLP-1 prescription medications in the United States.
During the previous year, demand for compounded GLP-1 drugs surged due to shortages of branded weight-loss and diabetes medications. However, the U.S. Food and Drug Administration (FDA) has since addressed the shortage by allowing increased production from branded pharmaceutical manufacturers, effectively reducing reliance on compounded alternatives. As a result, HealthWarehouse.com experienced a substantial drop in its partner services (business-to-business) prescription segment, which had previously benefited from the temporary supply gap.
The company reported that its prescription sales totaled $5.3 million for the quarter, compared to $14.4 million a year earlier, marking a decline of 62.8%. Within this category, B2B prescription revenue was particularly impacted, falling by approximately $8.8 million, or nearly 72%, year over year.
Despite this decline, the company noted positive momentum in its over-the-counter (OTC) segment. OTC sales increased to $934,000 from $577,000 in the same quarter last year, representing growth of 61.9%. This improvement was driven largely by stronger marketplace activity in its direct-to-consumer channels, although some offset was observed in its B2B OTC partnerships.
Gross Profit and Margin Expansion Despite Revenue Pressure
Although total revenue declined significantly, HealthWarehouse.com reported that gross profit for the first quarter of 2026 stood at $3.3 million. This represents a decrease of $1.2 million, or 27.3%, compared to the same period in 2025.
A notable highlight in the financial results was the substantial improvement in gross margin. The company’s gross margin increased from 30.2% in Q1 2025 to 52.1% in Q1 2026. Management attributed this improvement to a shift in product mix and pricing dynamics, particularly within prescription segments where higher-margin direct-to-consumer sales partially offset declines in lower-margin B2B volumes.
The company also noted that while OTC sales increased, they generally carry different margin profiles, which influenced overall profitability structure during the quarter.
Cost Management and Operating Expense Reduction
HealthWarehouse.com continued to implement cost-control measures during the quarter. Selling, general, and administrative (SG&A) expenses totaled $3.6 million, down from $4.3 million in the same period last year, representing a reduction of approximately 15.5%.
Several factors contributed to this decrease. Shipping and logistics-related costs fell by $712,000 due to lower order volumes. Additionally, salaries and related personnel expenses declined by $99,000, reflecting operational adjustments made in response to reduced sales activity.
However, these savings were partially offset by a $111,000 increase in advertising and marketing expenses. The company indicated that this investment supports long-term customer acquisition strategies and brand visibility in a competitive digital pharmacy market.
Net Loss and Adjusted EBITDA Performance
For the first quarter of 2026, HealthWarehouse.com reported a net loss of $361,000. This represents a decline of $539,000 compared to net income of $178,000 reported in the first quarter of 2025. The shift from profitability to loss was primarily driven by reduced revenue from compounded GLP-1 products, which had previously been a key driver of earnings.
On a non-GAAP basis, Adjusted EBITDA for the quarter was negative $28,000, compared with positive $561,000 in the same period a year earlier. The decline reflects the combined impact of lower sales volumes and changing product mix, partially offset by cost reductions in operations and administration.
The company also provided a reconciliation of Adjusted EBITDA, showing that depreciation, amortization, stock-based compensation, and other adjustments played a role in the final reported figure. While EBITDA (non-GAAP) stood at negative $181,000, adjustments such as stock-based compensation of $153,000 brought the final Adjusted EBITDA closer to break-even.
Strategic Shift Toward Technology and Artificial Intelligence
Beyond its financial performance, HealthWarehouse.com emphasized its strategic transformation toward a more technology-driven healthcare platform. The company stated that it is actively investing in proprietary systems designed to enhance operational efficiency, scalability, and customer experience.
A key development during the quarter was the announcement of a new strategic partnership with healthwords.ai, an artificial intelligence-focused healthcare company. This collaboration is expected to integrate AI capabilities into HealthWarehouse.com’s digital infrastructure.
According to company leadership, the partnership is designed to streamline internal operations, improve customer service capabilities, and support faster scaling of its digital pharmacy platform. AI is expected to assist in areas such as workflow automation, customer engagement, and data-driven decision-making.
Management stressed that while artificial intelligence will play a significant role in improving efficiency, human expertise will remain central to the company’s operations. The goal, they noted, is to use AI as a support tool rather than a replacement for staff, enabling employees to focus on higher-value tasks such as innovation, service quality, and strategic development.
Management Commentary on Business Outlook
President and Chief Executive Officer Joseph Peters acknowledged that the company’s financial performance was significantly influenced by external market changes, particularly the normalization of supply in GLP-1 medications.
He explained that the decline in revenue from compounded prescriptions was anticipated following the FDA’s intervention to stabilize supply chains and encourage branded manufacturers to increase production. While this transition has reduced short-term revenue, he emphasized that the company is actively expanding into new business areas to offset the impact.
Peters highlighted that HealthWarehouse.com is pursuing growth through strategic partnerships and technology-driven initiatives. He expressed confidence that the company’s scalable digital infrastructure positions it well for future expansion as new opportunities emerge in healthcare e-commerce and telehealth-related services.
Business Model and Market Position
HealthWarehouse.com operates as a fully licensed digital pharmacy serving customers across all 50 U.S. states. The company is recognized by the National Association of Boards of Pharmacy (NABP) as an Approved Digital Pharmacy, a designation that supports its credibility and regulatory compliance within the healthcare sector.
Its core business focuses on delivering prescription and over-the-counter medications through an online platform designed to improve affordability and accessibility. The company serves both individual consumers (B2C) and business partners (B2B), including healthcare providers and pharmacy networks.
Headquartered in Florence, Kentucky, HealthWarehouse.com positions itself as one of the early pioneers in online pharmacy services in the United States, with a mission centered on reducing healthcare costs and expanding access to medications.
Despite near-term financial challenges driven by regulatory changes and shifting market conditions, HealthWarehouse.com is positioning itself for long-term growth through diversification and technological innovation. The company’s emphasis on AI integration, operational efficiency, and expanded product offerings reflects a broader strategy to evolve beyond traditional pharmacy operations.
Management believes that continued investment in digital infrastructure, combined with strategic partnerships, will enable the company to adapt to changing healthcare dynamics and capture new growth opportunities in the evolving e-commerce healthcare landscape.
As the digital pharmacy sector continues to develop, HealthWarehouse.com’s performance in the coming quarters will likely depend on its ability to successfully transition from reliance on temporary market opportunities, such as compounded drug shortages, toward more sustainable and technology-driven revenue streams.
About HealthWarehouse.com
HealthWarehouse.com, Inc. (OTCQB: HEWA), a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (“NABP”). HealthWarehouse.com provides a platform focused on increasing access and reducing costs of healthcare products for consumers and business partners nationwide. Based in Florence, Kentucky, the Company operates America’s Leading Online Pharmacy and is a pioneer in affordable healthcare. As one of the first Approved Digital Pharmacies by the National Association of Boards of Pharmacy, HealthWarehouse.com services the mission of providing affordable healthcare and incredible patient services to help Americans
